Progressive multifocal leukoencephalopathy and spectrum of predisposing conditions: a 20-year retrospective cohort study in a tertiary center in São Paulo, Brazil

被引:1
作者
Mari, Julia Ferreira [1 ]
de Miranda, erique Jose Farias Peixoto [2 ]
Mendes-Correa, Maria Cassia [3 ]
Chow, Felicia C. [4 ,5 ]
Vidal, Jose Ernesto [1 ,6 ,7 ]
机构
[1] Univ Sao Paulo, Fac Med, Hosp Clin, Dept Molestias Infecciosas & Parasitarias, Sao Paulo, Brazil
[2] Inst Butantan, Ctr Ensaios Clin & Farmacovigilancia, Sao Paulo, Brazil
[3] Univ Sao Paulo, Lab Invest Med LIM 52, Fac Med, Hosp Clin, Sao Paulo, Brazil
[4] Univ Calif San Francisco, Dept Neurol, Weill Inst Neurosci, San Francisco, CA USA
[5] Univ Calif San Francisco, Dept Med, Infect Dis, San Francisco, CA USA
[6] Inst Infectol Emilio Ribas, Dept Neurol, Sao Paulo, Brazil
[7] Univ Sao Paulo, Hosp Clin, Fac Med, Lab Invest Med LIM 49, Sao Paulo, Brazil
关键词
Progressive multifocal leukoencephalopathy; JC virus; Outcome; Epidemiology; Brazil; DISEASE; NATALIZUMAB; PML; ERA; JC;
D O I
10.1007/s10072-024-07669-4
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BackgroundEpidemiological studies on predisposing conditions and outcomes of progressive multifocal leukoencephalopathy (PML) cases have been carried out exclusively in high-income countries. We aim to report and compare the main characteristics and outcomes of patients with PML and several underlying diseases in a referral center in a middle-income country.MethodsWe performed a retrospective cohort study of PML cases admitted to a tertiary care hospital in S & atilde;o Paulo, Brazil during 2000-2022. Demographic and PML-specific variables were recorded. One-year case-fatality rate and factors associated with death were identified using a multivariate Cox proportional hazards regression model.ResultsNinety-nine patients with PML were included. HIV infection (84.8%) and malignancy (14.1%) were the most prevalent underlying conditions. Other predisposing diseases were autoimmune/inflammatory diseases (5.1%) and solid organ transplantation (1.0%). One (1.0%) patient had liver cirrhosis and another (1.0%) patient was previously healthy. Focal motor deficits (64.2%) and gait instability (55.1%) were the most common signs. The one-year case-fatality rate was 52.5% (95% CI 42.2-62.7). The one-year case-fatality rate (95% CI) in patients with or without malignancy (85.7%, 95% CI 57.2-98.2% and 47.1%, 95% CI 36.1-58.2%, respectively) were statistically different (P = 0.009). Crude and adjusted Cox regression models identified malignancy as independently associated with death (adjusted HR = 3.92, 95% CI 1.76-8.73, P = 0.001).ConclusionsHIV/AIDS was the predisposing condition in 84.8% of PML cases. The one-year case-fatality rate was 52.5% and having a malignancy was independently associated with death. This study reports emerging data on the epidemiology and outcome of PML in a middle-income country.
引用
收藏
页码:365 / 379
页数:15
相关论文
共 35 条
[1]   Progressive multifocal leukoencephalopathy A 25-year retrospective cohort study [J].
Anand, Pria ;
Hotan, Gladia C. ;
Vogel, Andre ;
Venna, Nagagopal ;
Mateen, Farrah J. .
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2019, 6 (06)
[2]   Drug-induced Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: European Regulators' Perspective [J].
Anton, R. ;
Haas, M. ;
Arlett, P. ;
Weise, M. ;
Balabanov, P. ;
Mazzaglia, G. ;
Prieto, L. ;
Keller-Stanislawski, B. ;
Raine, J. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 102 (02) :283-289
[3]   PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY - A HITHERTO UNRECOGNIZED COMPLICATION OF CHRONIC LYMPHATIC LEUKAEMIA AND HODGKINS DISEASE [J].
ASTROM, KE ;
MANCALL, EL ;
RICHARDSON, EP .
BRAIN, 1958, 81 (01) :93-&
[4]   Commentary: Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies [J].
Berger, Joseph R. ;
Hartung, Hans-Peter .
FRONTIERS IN NEUROLOGY, 2023, 14
[5]  
Berger JR, 2014, HAND CLINIC, V123, P357, DOI 10.1016/B978-0-444-53488-0.00017-1
[6]   PML diagnostic criteria Consensus statement from the AAN Neuroinfectious Disease Section [J].
Berger, Joseph R. ;
Aksamit, Allen J. ;
Clifford, David B. ;
Davis, Larry ;
Koralnik, Igor J. ;
Sejvar, James J. ;
Bartt, Russell ;
Major, Eugene O. ;
Nath, Avindra .
NEUROLOGY, 2013, 80 (15) :1430-1438
[7]  
Berger Joseph R, 2011, Cleve Clin J Med, V78 Suppl 2, pS8, DOI 10.3949/ccjm.78.s2.03
[8]  
Brasil. Ministerio da Saude, 2022, Secretaria de Vigilancia em Saude. Departamento de Doencas de Condicoes Cronicas e Infeccoes Sexualmente Transmissiveis. Boletim Epidemiologico de HIV/Aids
[9]   A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy [J].
Chahin, Salim ;
Berger, Joseph R. .
JOURNAL OF NEUROVIROLOGY, 2015, 21 (06) :623-631
[10]   Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients [J].
Dahlhaus, Stefanie ;
Hoepner, Robert ;
Chan, Andrew ;
Kleiter, Ingo ;
Adams, Ortwin ;
Lukas, Carsten ;
Hellwig, Kerstin ;
Gold, Ralf .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2013, 84 (10) :1068-1074